Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PAVmed (PAVM) Common Equity (2022 - 2025)

Historic Common Equity for PAVmed (PAVM) over the last 4 years, with Q3 2025 value amounting to $32.5 million.

  • PAVmed's Common Equity changed N/A to $32.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.5 million, marking a year-over-year change of. This contributed to the annual value of -$7.0 million for FY2024, which is 7071.78% up from last year.
  • Per PAVmed's latest filing, its Common Equity stood at $32.5 million for Q3 2025.
  • Over the past 5 years, PAVmed's Common Equity peaked at $64.7 million during Q1 2022, and registered a low of -$43.3 million during Q3 2023.
  • For the 4-year period, PAVmed's Common Equity averaged around $6.8 million, with its median value being $9.2 million (2024).
  • As far as peak fluctuations go, PAVmed's Common Equity plummeted by 31966.34% in 2023, and later skyrocketed by 31868.29% in 2025.
  • Quarter analysis of 4 years shows PAVmed's Common Equity stood at $10.9 million in 2022, then crashed by 319.66% to -$24.0 million in 2023, then skyrocketed by 70.72% to -$7.0 million in 2024, then skyrocketed by 562.39% to $32.5 million in 2025.
  • Its Common Equity was $32.5 million in Q3 2025, compared to $37.5 million in Q2 2025 and $45.0 million in Q1 2025.